Loading news...
15,000 shares were exercised as options and immediately sold in the open market for a total of ~$1.9 million at around $127.71 per share on Jan. 22, 2026. This transaction represented 28.60% of Stapley's direct holdings, reducing his direct stake from 52,449 to 37,449 shares, with post-trade direct holdings valued at ~$4.7 million.
From a sector perspective, strength within Industrials and Information Technology offset relative weakness in Health Care. The October earnings report reinforced confidence in Comfort Systems' ability to convert a strong backlog and increasingly sophisticated project mix into sustained earnings growth. We did not make any adjustments to the position and continue to believe that the market opportunity remains robust.
GKOS is positioned for growth as interventional glaucoma adoption expands, iDose and iStent synergies build, and scale drives operating leverage despite margin pressures.
Shares of Glaukos Corporation (NYSE: GKOS - Get Free Report) were up 6% on Wednesday after BTIG Research raised their price target on the stock from $123.00 to $131.00. BTIG Research currently has a buy rating on the stock. Glaukos traded as high as $128.84 and last traded at $125.8350. Approximately 274,089 shares were traded during
ALISO VIEJO, Calif.--(BUSINESS WIRE)--Glaukos Corporation (NYSE: GKOS), an ophthalmic pharmaceutical and medical technology focused on novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases, today announced that the U.S. Food and Drug Administration (FDA) has approved an NDA labeling supplement allowing for re-administration of iDose® TR using a repeat treatment protocol. The FDA approval is in response to Glaukos' 2025 NDA labeling supplement application, and re.
ALISO VIEJO, Calif.--(BUSINESS WIRE)--Glaukos Corporation (NYSE: GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, plans to release fourth quarter and full year 2025 financial results after the market close on Tuesday, February 17, 2026. The company's management will discuss the results during a conference call and simultaneous webcast at 1:30 p.m. PT (4:30 p.m. ET) on February 17,.
Glaukos Corporation (GKOS) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
ALISO VIEJO, Calif.--(BUSINESS WIRE)--Glaukos Corporation (NYSE: GKOS), an ophthalmic pharmaceutical and medical technology focused on novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases, today announced its preliminary, unaudited net sales for the fourth quarter and full year ended December 31, 2025, and reaffirmed its full year 2026 revenue guidance. Preliminary and unaudited total net sales for the fourth quarter of 2025 are expected to be approximately $14.
Shares of Glaukos Corporation (NYSE: GKOS - Get Free Report) have earned a consensus rating of "Moderate Buy" from the sixteen analysts that are covering the stock, MarketBeat Ratings reports. Two equities research analysts have rated the stock with a sell recommendation, one has given a hold recommendation, twelve have issued a buy recommendation and one
GKOS appears well-positioned for long-term growth as iDose TR adoption accelerates and Epioxa secures FDA approval, although reimbursement and execution risks remain.
Texas Permanent School Fund Corp reduced its position in shares of Glaukos Corporation (NYSE: GKOS) by 70.4% during the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 19,655 shares of the medical instruments supplier's stock after selling 46,742 shares
ALISO VIEJO, Calif.--(BUSINESS WIRE)--Glaukos Corporation (NYSE: GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, today announced that its management is scheduled to participate in the 44th Annual J.P. Morgan Healthcare Conference on Tuesday, January 13, 2026, at 4:30 p.m. PT in San Francisco, CA. A live and archived webcast for these events, where applicable, will be available in.
Glaukos Corporation (GKOS) Presents at Citi Annual Global Healthcare Conference 2025 Transcript
Ameritas Investment Partners Inc. boosted its stake in Glaukos Corporation (NYSE: GKOS) by 14.0% in the second quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 5,709 shares of the medical instruments supplier's stock after purchasing an additional 702 shares during the quarter. Ameritas Investment Partners
GKOS gains momentum from iDose TR's strong launch and a growing pipeline, though reimbursement hurdles pose challenges ahead.
Glaukos (GKOS) reported earnings 30 days ago. What's next for the stock?
Creative Planning raised its stake in Glaukos Corporation (NYSE: GKOS) by 28.8% during the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 18,368 shares of the medical instruments supplier's stock after buying an additional 4,105 shares during the period. Creative
Glaukos Corporation ( GKOS ) UBS Global Healthcare Conference 2025 November 11, 2025 10:15 AM EST Company Participants Alex Thurman - Senior VP & CFO Christopher Lewis - Vice President of Investor Relations & Corporate Affairs Conference Call Participants Danielle Antalffy - UBS Investment Bank, Research Division Presentation Danielle Antalffy UBS Investment Bank, Research Division Good morning, everyone. Thank you so much for joining.
Baltimore-based Brown Capital Management sold 376,359 shares of Glaukos Corporation for an estimated $34.6 million in the third quarter. The transaction value equaled approximately 1.4% of fund's 13F assets under management at quarter-end.
Teacher Retirement System of Texas raised its position in shares of Glaukos Corporation (NYSE: GKOS) by 3.3% in the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 19,948 shares of the medical instruments supplier's stock after acquiring an additional 628 shares